Ferric derisomaltose
| Clinical data | |
|---|---|
| Trade names | Monoferric, Monofer |
| Other names | FDI |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C18H34FeO16+3 |
| Molar mass | 562.299 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ferric derisomaltose, sold under the brand name Monoferric among others, is a medication for the treatment of iron deficiency anemia in adults who have intolerance to oral iron or have had unsatisfactory response to oral iron or who have non-hemodialysis dependent chronic kidney disease (NDD-CKD).[4] It was approved for use in the United States in January 2020.[4][5][6] It is given intravenously.[4]
References
[edit]- ^ "Monofer iron (as ferric derisomaltose) 1000 mg/10 mL solution for injection vial (290834)". Therapeutic Goods Administration (TGA). 26 May 2022. Archived from the original on 14 April 2023. Retrieved 9 April 2023.
- ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 31 March 2024. Retrieved 31 March 2024.
- ^ "Regulatory Decision Summary for Monoferric". 23 October 2014. Archived from the original on 7 June 2022. Retrieved 7 June 2022.
- ^ a b c d "Monoferric- ferric derisomaltose solution". DailyMed. 24 January 2020. Archived from the original on 1 October 2020. Retrieved 16 February 2020.
- ^ This article incorporates text from this source, which is in the public domain.
- ^ "Drug Approval Package: Monoferric Injection". U.S. Food and Drug Administration (FDA). 7 May 2020. Archived from the original on 1 October 2020. Retrieved 13 August 2020.
 | This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |